Compare HubSpot Inc (HUBS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs McKesson Corporation — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 9.4× HubSpot Inc's market cap, and McKesson Corporation pays a 0.4% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and McKesson Corporation for 74 Days on average.
| HUBS | MCK | |
|---|---|---|
Market Cap | $11.56B | $108.46B |
Volume | 1,891,287 | 712,607 |
Sector | Technology | Health |
52-Week High | $494.58 | $995.69 |
52-Week Low | $170.39 | $725.17 |
Typical Hold Time | 78 Days | 74 Days |
Enterprise Value | $10.46B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 5.23% over the past day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, improving profitability, and positive cash flow trends, supported by an AI-focused strategy unveiled at its recent Analyst Day. Analyst consensus is bullish with a $243.65 price target, though high valuation multiples and competitive pressures remain considerations.
The outlook for HUBS is positive, driven by AI integration, margin expansion targets, and consistent revenue growth. Key risks include elevated valuation metrics, potential AI-driven demand headwinds, and insider selling activity. The stock presents a growth opportunity but requires monitoring of execution against ambitious targets and competitive dynamics in the CRM software space.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
